Agile Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Agile Therapeutics

04/05/2021 23:34

* Agile Therapeutics Inc  AGRX.OQ  reported a quarterly adjusted
loss of 20 cents​​ per share for the quarter ended in March. The
mean expectation of five analysts for the quarter was for a loss
of 21 cents per share.
* Revenue was $116.00 thousand​​;  analysts expected $159.20
thousand.
* Agile Therapeutics Inc's reported EPS for the quarter was a
loss of 20 cents​.
* The mean earnings estimate of analysts had fallen by
about 10.7% in the last three months.​ 
* In the last 30 days one analyst negatively revised an earnings
estimate and  
* Agile Therapeutics Inc shares had fallen by 14.4% this
quarter and lost 38.0% so far this year.
* The company reported a quarterly loss of $17.13 million.
* Wall Street's median 12-month price target for Agile
Therapeutics Inc is $7.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 4 at 10:34 p.m. GMT. ​All
figures in US Dollars.​